Skip to main content
OpenTrials
Completed

NCT Number: NCT03628638

Blood Sample Collection in Subjects Participating in a Lung Cancer Screening Program

The primary objective of this study is to establish a control population to assess performance of an investigational diagnostic test targeting lung neoplasms.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

50 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Achieve Clinical Research, Birmingham, Alabama, United States

Loading trial locations.

About this study

Subjects will be participating in a lung cancer screening program at enrollment. Subjects will have a blood sample collected within 60 days of a low-dose CT scan (LDCT). Subjects with nodules present on the LDCT or subjects with a clean LDCT scheduled for a 12-month follow-up may have another blood draw at 12 months.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is male or female, 50 years of age or older.
  • Subject meets one of two lung cancer screening criteria below.
  • Subject is a candidate for LDCT lung cancer screening and is scheduled for a baseline LDCT scan. There may be circumstances when a patient cannot have an LDCT scan (e.g., due to insurance issues). In these cases, it is allowable for a patient to have a CT scan in order to meet the inclusion criteria. OR
  • Subject has had previous LDCT scan(s) for lung cancer screening and the most recent LDCT scan prior to enrollment is negative for pulmonary nodules (Lung-RADS category 1, no nodules).
  • Subject understands the study procedures and is able to provide informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.

Exclusion criteria

  • Subjects with pulmonary nodules on the most recent LDCT scan prior to enrollment (Lung-RADS category 1 nodules with specific calcifications such as complete, central, popcorn, concentric rings and fat containing nodules are excluded).
  • Prior history of cancer within the past 5 years except for non-melanoma skin cancer.
  • Prior removal of the lung, excluding percutaneous lung biopsy.
  • Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.

Treatment and study plan

Blood Sample Collection

Other

Subjects participating in the study will have blood sample collected at enrollment. . For any subjects scheduled for a 12 month follow-up, additional blood samples will be collected at 12 months from enrollment.

Primary outcomes

  1. Biomarker Identification

    Time frame: 27 months

    Biomarkers under evaluation include differential methylation of nucleic acids and altered expression of proteins in blood to detect lung cancer

Sponsors and collaborators

Lead sponsor

Exact Sciences Corporation

Industry

Registry information

Official study title

2016-11: Blood Sample Collection in Subjects Participating in a Lung Cancer Screening Program

Acronym: 2016-11

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Aug 14, 2018
Registry last updated
Feb 15, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.